Purine-derived Phenylhydroxamate compounds induces cell death in hematological neoplasm models (2022)
- Authors:
- USP affiliated authors: LOTUFO, LETICIA VERAS COSTA - ICB ; PARISE FILHO, ROBERTO - FCF ; MACHADO NETO, JOÃO AGOSTINHO - ICB ; CARLOS, JORGE ANTONIO ELIAS GODOY - ICB
- Unidades: ICB; FCF
- DOI: 10.1016/j.htct.2022.09.265
- Assunto: ANTINEOPLÁSICOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Hematology, Transfusion and Cell Therapy
- ISSN: 2531-1379
- Volume/Número/Paginação/Ano: v. 44, Supl. 2, p. s157-s158, 2022
- Conference titles: Congresso Brasileiro de Hematologia, Hemoterapia e Terapia Celular (HEMO)
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by-nc-nd
-
ABNT
CARLOS, Jorge Antonio Elias Godoy et al. Purine-derived Phenylhydroxamate compounds induces cell death in hematological neoplasm models. Hematology, Transfusion and Cell Therapy. Amsterdam: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.htct.2022.09.265. Acesso em: 27 dez. 2025. , 2022 -
APA
Carlos, J. A. E. G., Almeida, L. C., Lima, K., Tavares, M. T., Costa-Lotufo, L. V., Parise Filho, R., & Machado Neto, J. A. (2022). Purine-derived Phenylhydroxamate compounds induces cell death in hematological neoplasm models. Hematology, Transfusion and Cell Therapy. Amsterdam: Instituto de Ciências Biomédicas, Universidade de São Paulo. doi:10.1016/j.htct.2022.09.265 -
NLM
Carlos JAEG, Almeida LC, Lima K, Tavares MT, Costa-Lotufo LV, Parise Filho R, Machado Neto JA. Purine-derived Phenylhydroxamate compounds induces cell death in hematological neoplasm models [Internet]. Hematology, Transfusion and Cell Therapy. 2022 ; 44 s157-s158.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1016/j.htct.2022.09.265 -
Vancouver
Carlos JAEG, Almeida LC, Lima K, Tavares MT, Costa-Lotufo LV, Parise Filho R, Machado Neto JA. Purine-derived Phenylhydroxamate compounds induces cell death in hematological neoplasm models [Internet]. Hematology, Transfusion and Cell Therapy. 2022 ; 44 s157-s158.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1016/j.htct.2022.09.265 - A novel HDAC inhibitor potentiates Venetoclax-induced apoptosis in acute myeloid leukemia cells
- Purine-derived phenylhydroxamate compounds reduce cell viability and modulate HDAC activity in hematological neoplasm models
- Compostos híbridos e usos dos referidos compostos
- Hybrid histone deacetylase kinase inhibitor potentiates venetoclax induced cell death in chronic lymphocytic leukemia
- Design and synthesis of new potential PI3K and HDAC6 hybrid inhibitors for cancer treatment
- Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms
- AD80, a multikinase inhibitor, as a potential drug candidate for colorectal cancer therapy
- The survivin/XIAP suppressant YM155 impairs clonal growth and induces apoptosis in JAK2V617F cells
- Enhancing venetoclax efficacy in leukemia through association with HDAC inhibitors
- miRNAs as prognostic predictors in acute myeloid leukemia [Editorial]
Informações sobre o DOI: 10.1016/j.htct.2022.09.265 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
